Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Aging kidneys under the microscope: could a simple test predict failure?

NCT ID NCT07765134

Knowledge-focused Sponsor: Huashan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study looks at thousands of Chinese adults aged 60 and older to understand how kidney function changes with age. Researchers are examining a range of blood and urine markers to see which ones best predict kidney failure, heart problems, and death. They are also testing different ways to estimate kidney function and building a model that could give early warning of decline. The goal is to help doctors spot at-risk individuals sooner, potentially preventing or delaying serious kidney disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a practical early-warning system that helps doctors identify older adults at high risk of kidney failure, potentially enabling earlier interventions to prevent or delay serious complications.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The early-warning model is developed and validated internally, so it may not work as well in other populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

5,588 people

The number who actually took part.

Started

Dec 2021

Finished

Sep 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population comprises adults aged 60 years or older selected from two established Chinese cohorts. The Rugao Longevity and Ageing Study primarily includes community-dwelling older adults, whereas the Shanghai Older-Adult Cohort includes older adults with comorbid conditions. Eligible participants had a baseline estimated glomerular filtration rate greater than 60 mL/min/1.73 m² and the clinical, follow-up, and biospecimen data required for the relevant analyses.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Enrollment in the Rugao Longevity and Ageing Study or the Shanghai Older-Adult Cohort. 2. Age 60 years or older, of either sex, with a baseline estimated glomerular filtration rate greater than 60 mL/min/1.73 m². 3. Availability of the baseline data required for the study, including blood pressure, body weight, body mass index, smoking and alcohol use, surgical history, family history, complete blood count, liver function, electrolytes, kidney function, serum cystatin C, blood glucose, urinalysis, and urinary albumin-to-creatinine ratio. 4. Availability of follow-up information sufficient to ascertain the prespecified clinical outcomes. 5. Clinically stable condition and adequate ability to understand and communicate at enrollment in the parent cohort. 6. Written informed consent for participation and the permitted research use of clinical data and stored biospecimens. Exclusion Criteria: 1. Missing essential baseline or follow-up data required for the relevant analysis. 2. Unavailability of stored blood or urine specimens required for the planned biomarker analysis. 3. Missing information on lifestyle, health-related behaviors, or social support required for the relevant analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease Kidney failure Kidney function decline

Contacts and locations

Locations

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, 200040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.